Pharmaco (Norfolk) Limited

	Page
Balance Sheet	1
Notes to the Financial Statements	2—4

Registered number: 8064169

		2025		2024
	Notes	£	£	£	£
FIXED ASSETS
Tangible Assets	4		144,913		144,913
Investments			1,940,448		1,940,448

			2,085,361		2,085,361
TOTAL ASSETS LESS CURRENT LIABILITIES			2,085,361		2,085,361

NET ASSETS			2,085,361		2,085,361

CAPITAL AND RESERVES
Called up share capital			186		186
Share premium account			627,714		627,714
Profit and Loss Account			1,457,461		1,457,461

SHAREHOLDERS' FUNDS			2,085,361		2,085,361

For the year ending 30 November 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.

On behalf of the board

Mr Mitul Patel

Director

9 June 2026

The notes on pages 2 to 3 form part of these financial statements.

1. General Information

Pharmaco (Norfolk) Limited is a private company, limited by shares, incorporated in England & Wales, registered number 8064169 . The registered office is Hunt's Pharmacy, 205 Plumstead Road, Norwich, Norfolk, NR1 4AB.

2. Accounting Policies

2.1. Basis of Preparation of Financial Statements

The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.

2.2. Tangible Fixed Assets and Depreciation

Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Freehold

over 50 years

2.3. Investment Properties

All investment properties are carried at fair value determined annually and derived from the current market rents and investment property yields for comparable real estate, adjusted if necessary for any difference in the nature, location or condition of the specific asset. No depreciation is provided for. Changes in fair value are recognised in the profit and loss account.

2.4. Taxation

Income tax expense represents the sum of the tax currently payable and deferred tax.

The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the statement of comprehensive income because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.

Deferred tax is recognised on timing differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable timing differences. Deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible timing differences can be utilised. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Deferred tax liabilities are presented within provisions for liabilities and deferred tax assets within debtors. The measurement of deferred tax liabilities and assets reflect the tax consequences that would follow from the manner in which the Company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.

Current and deferred tax are recognised in profit or loss for the year, except when they relate to items that are recognised in other comprehensive income or directly in equity, in which case current and deferred tax are recognised in other comprehensive income or directly in equity respectively.

2.5. Provisions

Provisions (ie liabilities of uncertain timing or amount) are recognised when there is an obligation at the reporting date as a result of a past event, it is probable that economic benefit will be transferred to settle the obligation and the amount of the obligation can be estimated reliably.

3. Average Number of Employees

Average number of employees, including directors, during the year was: 4 (2024: 4)

Page 2

Page 3

Pharmaco (Norfolk) Limited

Notes to the Financial Statements (continued)

For The Year Ended 30 November 2025

4. Tangible Assets

	Land & Property
	Freehold
	£
Cost
As at 1 December 2024	187,388

As at 30 November 2025	187,388

Depreciation
As at 1 December 2024	42,475

As at 30 November 2025	42,475

Net Book Value
As at 30 November 2025	144,913

As at 1 December 2024	144,913

5. Related Party Transactions

Summary of transactions with subsidiaries

T & C Hunt (Pharmacy) Limited

(100% subsidiary undertaking of Pharmaco (Norfolk) Limited)

The company owns a freehold property from which T & C Hunt (Pharmacy) Limited trades from. The company does not charge any rent for use of this property.

At the balance sheet date the amount due to T & C Hunt (Pharmacy) Limited was £0.00 (2024:£0.00) . The loan is interest free and repayable on demand.

T. & C. Hunt Limited

(100% subsidiary undertaking of Pharmaco (Norfolk) Limited)

At the balance sheet date the amount due to T. & C. Hunt Limited was £0.00 (2024:£0.00) . The loan is interest free and repayable on demand.

6. Ultimate Parent Undertaking and Controlling Party

Details of investments (including principal place of business of unincorporated entities) in which the company holds 20% or more of the nominal value of any class of share capital are as follows:

Undertaking Holding Proporation of voting rights &shares

Subsidiary undertakings

T. & C. Hunt Limited Ordinary shares 100%

T & C Hunt (Pharmacy) Limited Ordinary shares 100%

Registered office

205 Plumstead Road, Norwich, Norfolk, United Kingdom, NR1 4AB

Principal activity of T. & C. Hunt Limited is pharmaceutical chemists.

The profit for the financial period T. & C. Hunt Limited was £142,555.87 and the aggregate amount of capital and reserve at the end of the period was £1,483,497.38.

Principal activity of T & C Hunt (Pharmacy) Limited is pharmaceutical chemists.

The profit for the financial period T & C Hunt (Pharmacy) Limited was £972,934.43 and the aggregate amount of capital and reserve at the end of the period was £4,064,361.43.

7. Related party note

Page 3

Page 4

Pharmaco (Norfolk) Limited

Notes to the Financial Statements (continued)

For The Year Ended 30 November 2025

Mr Harshad Patel, Mr Mitul Patel, Mrs Divya Patel and Mrs Sonali Patel are directors of the company.

At the end of the year amount owed by the company to the directors is £0.00 (2024: £0.00).

During the year the company has not declared any dividends £0.00. (2024: £0.00).

Page 4